According to the report titled ‘Pulmonary Arterial Hypertension Market Size By Drug Class (Prostacyclin And Prostacyclin Analogs, Soluble Guanylate Cyclase (SGC) Stimulators, Endothelin Receptor Antagonist (ERA), Phosphodiesterase 5 (PDE-5), Vasodilators), By Route of Administration (Oral, Intravenous, Inhalation), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027,’ available with MarketStudyReport, global pulmonary arterial hypertension market is expected to exhibit exponential growth during 2021-2027.
 

Increasing occurrences of cardiovascular diseases due to unhealthy habits like smoking & drinking, coupled with soaring proportion of the geriatric population are factors propelling the growth of global pulmonary arterial hypertension market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4202298/

Moreover, rise in research & development efforts for improved drugs supported by favorable government policies is further accelerating the progress of the industry. 

During the COVID-19 pandemic, patients with prevailing heart ailments were extremely vulnerable as the virus escalated their disease, particularly in the population aged 65 & above. Hence, the virus outbreak has had an intense impact on the market outlook. 

Besides, the rising focus on developing effective therapies among prominent players of the market is likely to create lucrative opportunities in the forthcoming years. 

Based on drug class, the vasodilators segment of worldwide pulmonary arterial hypertension industry was worth USD 1,365 million in 2020 and is slated to gain traction in the coming years, owing to the higher survival rate of critical patients being treated with vasodilators. 

In terms of route of administration, the intravenous segment accounted for a considerable market share in 2020 and is anticipated to amass USD 1,555 million by the end of the analysis period, as intravenous administration offers effective and fast-acting drug delivery.

From a regional standpoint, Middle East & Africa market was valued at USD 124 million in the year 2020 and is poised to generate sizeable returns during the assessment timeframe, because of the soaring prevalence of the disease throughout the region. 

The competitive landscape of global pulmonary arterial hypertension market is defined by companies such as United Therapeutics Corporation, Bayer AG, Pfizer, Inc., Eli Lilly and Company, Johnson & Johnson, Gilead Sciences, Inc., and GlaxoSmithKline plc among others.